Subject: Cervical Cancer (HPV) Vaccine*

Effective Date: July 25, 2006

Department(s): Utilization Management

Policy: Quadrivalent and bivalent human papilloma virus (HPV) vaccines are reimbursable under Plans administered by QualCare, Inc., under the circumstances specified in this policy.

Objective: To assure proper and consistent reimbursement and to define the population for which HPV vaccines are reimbursable.

Procedure:

1. Quadrivalent, bivalent and nonavalent HPV vaccines are covered as part of the immunizations in each Plan’s wellness policies.

2. The CPT codes for these vaccines are:
   a. 90649 (quadrivalent)
   b. 90650 (bivalent)
   c. 90651 (nonavalent)

3. Quadrivalent, bivalent and nonavalent HPV vaccines, which are administered as a series of three injections, are covered for males and females from age 9 years through age 26 years.

4. If the three-injection series is begun before the individual’s 27th birthday, the remaining injections in the series are reimbursable even if they continue past the 27th birthday.
References


Centers for Disease Control and Prevention. Recommendations on the use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(50):1705-8(Dec)


Dooren JC. Ill Effects Likely Not Tied to Gardasil, Study Says. Wall Street Journal 10/23/08 p B9


Haupt RM. GARDASIL® Update: End-of-Study (16-26 year-olds) Adult Women (24-45 year-olds). Report to ACIP. February 27, 2008


---FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Disease in Females Caused by Human Papillomavirus. FDA News 2006;P06-77 (Jun 8)


---Who should be vaccinated against human papillomavirus? Lancet Infec Dis 2006;6(1):1 (Jan)


*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.

CONFIDENTIAL - NOT FOR DISTRIBUTION OUTSIDE OF QUALCARE